Menu

BeyondSPX has rebranded as EveryTicker. We now operate at everyticker.com, reflecting our coverage across nearly all U.S. tickers. BeyondSPX has rebranded as EveryTicker.

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (3734)

Company Market Cap Price
ISRG Intuitive Surgical, Inc.
Intuitive Surgical directly manufactures robotic surgical systems and instruments, i.e., core surgical equipment.
$166.33B
$469.10
+2.41%
PFE Pfizer Inc.
Pfizer's vaccines portfolio (e.g., Comirnaty and other RSV vaccines) is a core, revenue-driving product line.
$156.70B
$27.56
+1.25%
WELL Welltower Inc.
Healthcare Services & Facilities – Welltower's properties function as healthcare facilities and related operations.
$144.49B
$210.53
-1.86%
DHR Danaher Corporation
Danaher directly sells diagnostic equipment/instruments (e.g., Cepheid and Beckman Coulter diagnostics platforms like DxC 500i, DXi 9000).
$137.56B
$194.78
+0.52%
SYK Stryker Corporation
Stryker directly manufactures surgical devices and instruments used in operating rooms.
$131.29B
$343.30
+1.45%
BMY Bristol-Myers Squibb Company
Opdivo is a monoclonal antibody immuno-oncology therapy, a core direct product in BMY's Growth Portfolio.
$122.49B
$60.17
+2.06%
VRTX Vertex Pharmaceuticals Incorporated
Vertex is a large-cap pharma/biotech with a diversified, revenue-generating portfolio anchored by CFTR modulators and expanding pipeline.
$111.94B
$441.08
+1.25%
HCA HCA Healthcare, Inc.
HCA operates a large network of hospitals and provides inpatient hospital services.
$111.36B
$487.84
+1.01%
MDT Medtronic plc
Medtronic's core cardiovascular devices include leadless pacing, ablation technologies, and related interventional products.
$110.50B
$86.19
+0.62%
MCK McKesson Corporation
McKesson distributes medical devices and biometrics through its Medical-Surgical Solutions, aligning with the medical devices category.
$106.93B
$866.07
-0.15%
CVS CVS Health Corporation
CVS Health includes health benefits/insurance via Aetna, a core health insurance offering.
$98.13B
$77.25
+0.61%
BSX Boston Scientific Corporation
Directly sells Cardiology Devices (e.g., WATCHMAN LAAC, ablation catheters, stents) and other interventional cardiology therapies.
$95.22B
$64.23
+1.28%
WM Waste Management, Inc.
WM Healthcare Solutions provides regulated medical waste management and secure information destruction services.
$90.22B
$223.88
-0.09%
REGN Regeneron Pharmaceuticals, Inc.
Regeneron’s core business centers on monoclonal antibody therapeutics (e.g., Dupixent, Libtayo).
$78.88B
$750.82
+0.65%
CI Cigna Corporation
Health insurance products and related services are CI's core offering.
$74.43B
$278.59
+0.80%
ELV Elevance Health Inc.
Direct health insurance provider (Health Insurance) – Elevance Health's core revenue comes from health benefits and risk-sharing with members.
$71.79B
$322.75
+2.19%
MFC Manulife Financial Corporation
Health insurance products via group/employee benefits segments.
$65.39B
$38.81
+0.48%
AFL Aflac Incorporated
Aflac sells health-related supplemental insurance (e.g., cancer insurance) as a core product, aligning with Health Insurance.
$60.02B
$114.50
+0.69%
TAK Takeda Pharmaceutical Company Limited
Entrvyo/vedolizumab and other monoclonal antibody therapies place Takeda in Monoclonal Antibody Therapeutics.
$55.67B
$17.82
+0.25%
← Previous
1 2 3 4 ... 38
Next →
Showing page 2 of 38 (3734 total stocks)

Loading company comparison...

Loading research report...

BMY Bristol-Myers Squibb Company

Bristol‑Myers Squibb Licenses Five Autoimmune Drug Programs to New Biotech Beeline Medicines

Apr 16, 2026
DHR Danaher Corporation

Cepheid and Oxford Nanopore Expand Partnership to Accelerate Rapid Pathogen Identification

Apr 15, 2026
ELV Elevance Health Inc.

California Judge Dismisses Elevance Health’s Surprise Billing Lawsuit, Elevance Plans Appeal

Apr 15, 2026
REGN Regeneron Pharmaceuticals, Inc.

Regeneron and Telix Forge Radiopharmaceutical Collaboration to Target Solid Tumors

Apr 14, 2026
DHR Danaher Corporation

Beckman Coulter Receives CE Mark for Rapid Bacterial‑Viral Infection Test, Expanding European Diagnostics Portfolio

Apr 13, 2026
REGN Regeneron Pharmaceuticals, Inc.

Regeneron Secures EU Approval for Dupixent in Children Aged 2‑11 with Chronic Urticaria

Apr 13, 2026
SYK Stryker Corporation

Stryker to Acquire Amplitude Vascular Systems, Expanding Its Peripheral Vascular Platform

Apr 13, 2026
BMY Bristol-Myers Squibb Company

Bristol‑Myers Squibb Partners with Oxford BioTherapeutics to Advance Solid‑Tumor T‑Cell Engagers

Apr 09, 2026
MDT Medtronic plc

Medtronic Expands Stealth AXiS Platform with GE bkActiv Ultrasound Integration

Apr 09, 2026
VRTX Vertex Pharmaceuticals Incorporated

Vertex Secures Exclusive License to Halozyme’s Hypercon Microparticle Technology for Up to Three Drug Targets

Apr 07, 2026
REGN Regeneron Pharmaceuticals, Inc.

Regeneron Secures $200 Million Deal with TriNetX to Expand Genomic and Proteomic Data Access

Apr 03, 2026
PFE Pfizer Inc.

Belgian Court Orders Poland, Romania to Pay $2.2 B for Pfizer COVID‑19 Vaccines

Apr 02, 2026
REGN Regeneron Pharmaceuticals, Inc.

Regeneron’s EYLEA HD Receives FDA Approval to Extend Dosing Intervals to 20 Weeks

Apr 02, 2026
BMY Bristol-Myers Squibb Company

Janux Therapeutics Receives $35 Million Milestone Payment from Bristol‑Myers Squibb After Development Candidate Nomination

Apr 01, 2026
MDT Medtronic plc

Tempus AI and Medtronic Announce 27% Increase in Timely Valvular Heart Disease Treatment from ALERT Trial

Apr 01, 2026
PFE Pfizer Inc.

Pfizer and BioNTech Halt U.S. COVID‑19 Vaccine Trial Amid Low Enrollment

Apr 01, 2026
VRTX Vertex Pharmaceuticals Incorporated

Vertex Gains FDA Approval for Expanded ALYFTREK Label, Enabling Treatment for 95% of U.S. Cystic Fibrosis Patients

Apr 01, 2026
AFL Aflac Incorporated

Aflac Re Bermuda Secures First External Reinsurance Deal with Japan Post Insurance

Mar 31, 2026
BSX Boston Scientific Corporation

Boston Scientific Receives FDA 510(k) Clearance for Asurys Fluid Management System

Mar 30, 2026
BMY Bristol-Myers Squibb Company

Bristol‑Myers Squibb Reports Successful Phase 3 Results for Camzyos in Adolescents with Hypertrophic Cardiomyopathy

Mar 29, 2026
BSX Boston Scientific Corporation

Boston Scientific Reports Landmark Clinical Trial Results for Pulmonary Embolism and Atrial Fibrillation

Mar 29, 2026
BSX Boston Scientific Corporation

Boston Scientific Reports Landmark CHAMPION‑AF Trial Results for WATCHMAN FLX Device

Mar 28, 2026
MDT Medtronic plc

Medtronic Secures FDA Clearance for Stealth AXiS System in Cranial and ENT Surgeries, Expanding Multi‑Specialty Platform

Mar 27, 2026
REGN Regeneron Pharmaceuticals, Inc.

Regeneron and Sanofi Secure First Targeted Approval for Bullous Pemphigoid in Japan

Mar 24, 2026
MDT Medtronic plc

Medtronic Secures FDA Approval for First‑In‑Class Left Bundle Branch Defibrillation Lead

Mar 23, 2026
PFE Pfizer Inc.

Pfizer and Valneva Report 73% Efficacy for Lyme Disease Vaccine, but Trial Misses Primary Endpoint

Mar 23, 2026
BMY Bristol-Myers Squibb Company

Bristol‑Myers Squibb Gains FDA Approval for Opdivo Plus AVD in Untreated Hodgkin Lymphoma

Mar 21, 2026
PFE Pfizer Inc.

Pfizer Reports Positive Results for Talzenna‑Xtandi Combination in Metastatic Castration‑Sensitive Prostate Cancer

Mar 20, 2026